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Abstract
Background: Identification of tumor suppressor genes (TSGs) silenced by CpG methylation uncovers the molecular
mechanism of tumorigenesis and potential tumor biomarkers. Loss of heterozygosity at 11q25 is common in multiple
tumors including nasopharyngeal carcinoma (NPC). OPCML, located at 11q25, is one of the downregulated genes we
identified through digital expression subtraction.
Methodology/Principal Findings: Semi-quantitative RT-PCR showed frequent OPCML silencing in NPC and other common
tumors, with no homozygous deletion detected by multiplex differential DNA-PCR. Instead, promoter methylation of OPCML
was frequently detected in multiple carcinoma cell lines (nasopharyngeal, esophageal, lung, gastric, colon, liver, breast,
cervix, prostate), lymphoma cell lines (non-Hodgkin and Hodgkin lymphoma, nasal NK/T-cell lymphoma) and primary
tumors, but not in any non-tumor cell line and seldom weakly methylated in normal epithelial tissues. Pharmacological and
genetic demethylation restored OPCML expression, indicating a direct epigenetic silencing. We further found that OPCML is
stress-responsive, but this response is epigenetically impaired when its promoter becomes methylated. Ecotopic expression
of OPCML led to significant inhibition of both anchorage-dependent and -independent growth of carcinoma cells with
endogenous silencing.
Conclusions/Significance: Thus, through functional epigenetics, we identified OPCML as a broad tumor suppressor, which is
frequently inactivated by methylation in multiple malignancies.
Citation: Cui Y, Ying Y, van Hasselt A, Ng KM, Yu J, et al. (2008) OPCML Is a Broad Tumor Suppressor for Multiple Carcinomas and Lymphomas with Frequently
Epigenetic Inactivation. PLoS ONE 3(8): e2990. doi:10.1371/journal.pone.0002990
Editor: Simon Williams, Texas Tech University Health Sciences Center, United States of America
Received June 17, 2008; Accepted July 24, 2008; Published August 20, 2008
Copyright:  2008 Cui et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project was supported by a Hong Kong RGC Central Allocation Grant (CA06/07.SC03 to QT) and a Chinese University of Hong Kong direct grant.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: qtao@clo.cuhk.edu.hk
¤ Current address: Wyeth Research, Translational Medicine Research Collaboration, Dundee, United Kingdom
. These authors contributed equally to this work.
Introduction
Epigenetic silencing of tumor suppressor genes (TSGs) is
frequently involved in tumor development and progression [1].
Aberrant methylation of promoter CpG islands (CGI) represents a
major mechanism of this epigenetic inactivation, which leads to
the binding of transcription repressors, compressed chromatin,
and transcription silencing [2]. Identification of candidate TSGs
silenced by promoter methylation thus uncovers the epigenetic
mechanism of carcinogenesis and also identifies new epigenetic
tumor markers for early cancer detection [3].
Nasopharyngeal carcinoma (NPC) is a prevalent tumor in
Southern China and Southeast Asia, particularly in the Cantonese
population [4]. Although virtually all NPC has been shown to be
strongly associated with Epstein-Barr virus (EBV) infection [5,6], the
molecular mechanism of NPC pathogenesis is still poorly elucidated
[4]. Searches for putative TSGs have identified only few candidates,
with tumor-specific promoter methylation, such as BLU and
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RASSF1A at 3p21 [7,8], CADM1/TSLC1 at 11q23.1 [9]; THY1/
CD90 at 11q22.3 [10], CDH1 at 16q22.1 [11], RASAL1 [12],
ADAMTS18 and CDH13 at 16q23 [13,14]. These limited findings
suggest that additional candidate TSGs are yet to be identified for this
tumor.
We previously used a new strategy to search for candidate TSGs
genome-wide in NPC, through combining Differential Gene
Expression Displayer (DGED) analysis with reported loss of
heterozygosity (LOH) data of NPC (Liu & Tao, manuscript in
preparation). This strategy revealed a number of putative TSGs
that were down-regulated in NPC and also located at LOH loci.
One of the in silico identified genes is OPCML (opioid binding
protein/cell adhesion molecule-like gene), also known as OBCAM
(opioid binding cell adhesion molecule), belonging to the IgLON
(OPCML, LSAMP, NEGR1 and HNT) family of glycosylpho-
sphatidylinositol (GPI)-anchored cell adhesion molecules that are
highly expressed in the nervous system [15–18] and involved in
cell adhesion and cell-cell recognition [19]. Located at 11q25,
OPCML was the first IgLON member linked to tumorigenesis. It
was initially identified as a TSG for epithelial ovarian cancer,
being frequently inactivated by hemizygous deletion and promoter
methylation [20]. More recent studies also demonstrated that
OPCML is highly methylated in lung adenocarcinoma [21] and
down-regulated in gastric and brain carcinomas [22,23], however
no study has been reported for NPC and other tumors yet.
We thus systematically studied its alteration in a series of
common tumors. As alternative splicing is a feature of OPCML
[23] and other IgLONs (e.g. LSAMP) [24], we first studied its
alternative splicing. We then examined its epigenetic inactivation
in NPC and multiple other tumors which have not been studied
for this gene, including esophageal, lung, gastric, hepatocellular,
colorectal, breast, cervical and prostate carcinomas, as well as non-
Hodgkin and Hodgkin lymphomas. We further found that OPCML
is a stress- and p53-responsive gene; however, its stress response is
epigenetically disrupted when the promoter becomes methylated.
Ectopic expression of OPCML in tumor cell lines with endogenous
silencing led to strong inhibition of cell colony formation,
demonstrating that OPCML acts as a broad tumor suppressor.
Results
Identification of novel splicing variants of OPCML
OPCML contains 7 exons and is transcribed from telomere to
centromere (Fig. 1A). Among the four IgLON family members,
OPCML shares the highest homology to HNT that lies approxi-
mately 80 kb centromeric to OPCML in the opposite orientation.
Two alternative splice transcripts of OPCML, variant 1 (v1)
(NM_002545) and variant 2 (v2) (NM_001012393), were previ-
ously identified in human, which differ only in their 59 exons
(Fig. 1B) but encode an identical mature protein [23].
We determined the transcription start sites of OPCML using 59-
Rapid Amplification of cDNA Ends (59-RACE) in human brain
and testis RNA. We obtained four PCR products of different sizes
(Fig. 1C). Sequence analysis of the major PCR product
(EU562296) indicated it as the v2 variant. The 59 end of v2 was
found to be shorter (,110-bp downstream) than the published
data, but its transcription start site matched exactly the DBTSS
prediction (DataBase of Transcriptional Start Sites, http://dbtss.
hgc.jp/). Three minor splice forms were also identified, designated
v4 (EU562298), v5 (EU562299), and v6 (EU562300) (Fig. 1B and
1C left panel). Our 59-RACE gel electrophoresis failed to reveal a
PCR band for the major transcript variant v1 in brain and testis
tissues, probably due to the presence of a too large exon 1 (,1-kb)
for v1, which would result in low amplification efficiency. Thus, we
performed further RT-PCR using the 59-RACE product of brain
and testis as template and primers specific to v1 (v1F/R4 and
v1F0/R4; Fig. 1C right panel), to check whether v1 was expressed
in normal tissues. This analysis did confirm the expression of v1
(EU562295) and identified another alternatively spliced variant v3
(EU562297) which is widely expressed in adult tissues (Fig. 1D).
Further analysis using primers specific to the common exons (exon
2 and 3) of OPCML variants in cell lines without both v1 and v2
transcripts revealed the presence of even more unidentified,
alternative promoter usage (Fig. 1F).
Broad expression of OPCML-v1 and v2 major variants in
normal tissues
Previously, OPCML was shown to be strongly expressed in brain
and normal ovarian epithelia [20]. We further assessed its
expression in 33 normal human adult and fetal tissues by semi-
quantitative PCR with specific primers targeting the v1, v2, or
common exons (exon 2 and 3) (Fig. 1B), respectively. OPCML-v1
was widely expressed in all normal adult and fetal tissues except for
placenta and peripheral blood mononuclear cells (PBMC), though
at varying levels (highly expressed in brain, kidney, spleen,
stomach, trachea, testis, cervix, ovary and prostate, and weakly
in lung, breast, and bone marrow) (Fig. 1E). Compared to v1,
OPCML-v2 displayed a more tissue-specific expression pattern in
adult tissues, with expression absent or barely detectable in kidney,
spleen, pancreas, breast, testis, lung, colon, liver, testis and bone
marrow. In contrast to its expression in adult tissues, OPCML-v2
was expressed at moderate to high levels in all fetal tissues except
for placenta. These results suggest that both v1 and v2 are likely to
have important functions in embryonic development.
Silencing of OPCML by CpG methylation in tumor cell
lines
We identified OPCML as a down-regulated gene through in silico
subtraction. We further validated its expression in a large
collection of carcinoma and lymphoma cell lines by semi-
quantitative RT-PCR. It was found that OPCML-v1 expression
was dramatically reduced or completely silenced in multiple
carcinoma cell lines of nasopharynx, esophagus, breast, cervix,
stomach, lung, colon, liver and prostate, as well as in virtually all
lymphoma cell lines examined (Fig. 2C and Figure S1), but readily
detected in glioma cell lines (Fig. 2D). In contrast, its expression
was readily detected in most non-tumor cell lines, including
normal mammary (HMEC, HMEpC) and prostate (PrEC-6)
epithelial cell line, and immortalized but non-transformed
epithelial cell lines (nasopharyngeal, NP69; esophageal, NE1,
NE3 and Het-1A; prostate, MLCSV40). Thus, the downregulation
of OPCML-v1 appeared to be tumor-specific. Notably, expression
of OPCML-v2 remained undetectable in virtually all cell lines
evaluated, including normal cell lines. Given its limited tissue
expression pattern and the fact that v2 promoter is not a CpG
island with very few CpG sites, the mechanism of OPCML-v2
silencing is not pursued further in the current study.
As methylation of promoter CGI is a well-recognized epigenetic
mechanism of TSGs silencing [2], we thus examined the potential
promoter regions of the 2 major variants (v1 and v2). The
OPCML-v1 (NM_002545) and v2 (NM_001012393) sequence
upstream of their exon 1 was retrieved from the NCBI database
and analyzed using promoterinspector (http://www.genomatix.
de) and CpG Island Searcher (http://ccnt.hsc.usc.edu/cpgis-
lands2). This analysis predicted a promoter for OPCML-v1,
located within a typical CGI spanning the published transcription
start site of v1, which was also confirmed by our 59-RACE analysis
Methylation of OPCML
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Figure 1. Identification of novel splicing variants of OPCML and its expression in normal human tissues. (A) Genomic organization of the
11q25 locus with the two known genes OPCML and HNT. Transcriptional orientations are shown by curved arrows. (B) Different promoter usage and
alternative splicing of OPCML. Alternative mRNA transcripts are shown aligned from 59 to 39 on a virtual genome. The 59-end of OPCML-v1 assembled
by ECgene (Genome Annotation for Alternative Splicing, http://genome.ewha.ac.kr/ECgene/) was adapted to this alignment. (C) Left panel:
determination of transcription start sites of OPCML transcripts by 59-RACE. Right panel: expression of OPCML-v1 and v3 in brain and testis by semi-
quantitative RT-PCR using 59-RACE product as the template. Primer pair v1F/R4 amplifies one band that is specific to v1. Primer pair v1F0/R4 amplifies
two bands corresponding to v1 and v3, respectively. (D) Expression of OPCML-v1 and v3 in adult tissues by semi-quantitative RT-PCR. Primer pair
v1F0/R4 amplifies two bands corresponding to v1 and v3, respectively. The specific and non-specific bands have been confirmed by direct
sequencing. (E) Expression of OPCML-v1 and v2 in human normal adult and fetal tissues. Primer pair v1F/R4, v2F/R4 and F3/R2 are specific to the v1-,
v2-transcripts, and common exons (exon 2 and 3) of OPCML , respectively. Sk.M., skeletal muscle. (F) Possible transcription of OPCML from other
unidentified alternative promoters. Expression of OPCML in normal and tumor cell lines was analyzed by semi-quantitative RT-PCR using primers (F3/
R2) specific to common exons (exon 2 and 3) of OPCML. Expression of OPCML-v1 or v2 is indicated as ‘‘+’’, while downregulation or silencing is
indicated as ‘‘2’’. OPCML-v1 promoter methylation status in each cell line is also shown. M, methylated; U, unmethylated. Transcription of OPCML
from unknown alternative promoters was found in some tumor cell lines (underlined) where the OPCML-v1 promoter is methylated and silenced and
v2 expression is also silenced.
doi:10.1371/journal.pone.0002990.g001
Methylation of OPCML
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(Fig. 2A). We did not find any obvious CGI or predicted promoter
in the region upstream of the exon 1 of v2, indicating that either
the v2 promoter is not a typical one or the published 59-end
sequence of v2 is not complete yet. Thus, we focused on the role of
promoter CGI methylation in the silencing of OPCML-v1. We first
validated that our methylation-specific PCR (MSP) was specific,
which did not give any non-specific signal for the unbisulfate DNA
(Fig. 2B) and revealed the methylation of OPCML-v1 in silenced
placenta tissue (Figure S2). Next, v1 promoter methylation was
detected in most tumor cell lines with downregulated or silenced
expression (6/6 nasopharyngeal, 15/17 esophageal, 5/5 lung, 17/
17 gastric, 11/11 colorectal, 6/13 hepatocellular, 9/10 breast, 8/8
cervical and 2/3 prostate carcinoma cell lines, and 20/21
lymphoma cell lines) (Fig. 2C, Figure S1 and Table 1), while no
Figure 2. Epigenetic inactivation of OPCML in multiple tumor cell lines. (A) Schematic structure of the v1 (NM_002545) CGI, with its exon 1,
predicted promoter region, MSP region and BGS region indicated. Each short vertical line represents one CpG site. The v2 promoter is also shown. (B)
Validation of the specificity of the MSP system. No signal was detected using the unbisulfited DNA from several tumor cell lines. (C) Representative
analyses of OPCML v1 and v2 (NM_001012393) expression by semi-quantitative RT-PCR and methylation status of v1-CGI by MSP in tumor cell lines
and normal controls. M, methylated; U, unmethylated. Immortalized normal epithelial cell lines (NE1, NE3, Het-1A, NP69, CCD 841, MLCSV40) and
normal epithelial cell lines (HMEC, HMEpC and PrEC-6) with underlined names were used as normal controls. RC170N/h and RC165N/h are
telomerase-immortalized benign prostate epithelial cell lines, RC92a/h and RC58T/h/SA#4 are telomerase-immortalized prostate tumor derived cell
lines. (D) Expression and methylation of OPCML in glioma cell lines.
doi:10.1371/journal.pone.0002990.g002
Methylation of OPCML
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methylation was detected in the eight normal epithelial cell lines,
demonstrating that v1 promoter methylation is well correlated
with its expression status (Fig. 2C).
To further confirm the MSP results and examine the
methylation status of the v1 CGI in more detail, we performed
high-resolution bisulfite genome sequencing (BGS) analysis of 90
CpG sites within the island, spanning almost the entire predicted
promoter. The BGS results were consistent with the MSP analysis,
with all the promoter alleles extensively methylated in silenced cell
lines and only scattered methylated CpG sites detected in non-
tumor cell lines (Fig. 3). These results thus revealed a strong
correlation between OPCML-v1 promoter methylation and its
transcriptional silencing in tumor cell lines.
Pharmacologic and genetic demethylation restored
OPCML-v1 expression
To determine whether methylation directly mediates OPCML
silencing, carcinoma and lymphoma cell lines (MB231, Hep3B,
HepG2, SNU398, SW480 and L1236) were treated with the DNA
methyltransferase inhibitor 5-aza-29-deoxycytidine (Aza), together
with or without histone deacetylase inhibitor Trichostatin A
(TSA). The treatment resulted in the restoration of OPCML-v1
expression in all tumor cell lines (Fig. 4A). OPCML-v1 could also
be induced in the colorectal cancer cell line HCT116 which is
completely methylated for this gene, by genetic demethylation
through double knock-out of both DNA methyltransferases
DNMT1 and DNMT3B (DKO cell line) [25] (Fig. 4B). Concom-
itantly, the v1 promoter alleles were almost completely demeth-
ylated in DKO cells as confirmed by high-resolution BGS analysis
(Fig. 4C), suggesting that the maintenance of OPCML methylation
is mediated by DNMT1 and DNMT3B together, like other bona-fide
TSGs that we and others have examined [12,13,26]. Interestingly,
OPCML-v2 could not be activated in any drug treated cell line or
DKO cell line (Fig. 4A, 4B), suggesting that the expression of
OPCML-v2, being tissue-specific, is controlled by other intrinsic
mechanism(s), and that its silencing in multiple carcinoma cell lines
is controlled by methylation-independent mechanism or, less
likely, that its upregulation level is below the limit of detection.
OPCML downregulation was not due to genetic deletion
The downregulation of OPCML in multiple tumor cell lines
might also result from genetic deletion, as it resides in the
frequently deleted 11q25 locus. Hemizygous deletion of OPCML
was also often detected in epithelial ovarian cancer [20]. We thus
performed multiplex differential genomic DNA PCR to detect
OPCML deletion for a region spanning the frequently deleted
marker D11S4085 in epithelial ovarian cancer. No homozygous
deletion was detected in any silenced tumor cell line (Fig. 5).
Furthermore, our high-resolution 1-Mb array comparative
genomic hybridization (aCGH) analysis of NPC and ESCC cell
lines [12,26,27] revealed the hemizygous deletion of OPCML in
only 2 out of 15 cell lines (data not shown). Thus, downregulation
of OPCML appears not to be due to genetic deletion, but rather
predominantly to epigenetic silencing.
Frequent methylation of OPCML in multiple primary
tumors
We further investigated the OPCML-v1 promoter methylation in
a large collection of primary tumors, some with corresponding
normal tissues as controls (Fig. 6A and Table 1). OPCML-v1
methylation was detected in 98% (42/43) of NPC, 66% (21/32) of
esophageal, 91% (10/11) of breast, 64% (7/11) of gastric, 94%
(17/18) of colorectal, 57% (4/7) of hepatocellular and 88% (7/8)
of cervical carcinomas, as well as in 100% (10/10) of Burkitt
lymphoma and 89% (8/9) of nasal lymphoma. Methylation was
also detected with low frequency in paired surgical marginal tissues
from patients with esophageal carcinoma at the rate of 16% (5/
32), and with breast carcinoma at the rate of 25% (1/4), which
might be due to the presence of small number of tumor cells
disseminated into the adjacent non-tumorious region or an early
tumor in the adjacent normal regions. Basically no methylation
was detected in normal epithelial tissues (nasopharynx, esophagus
Table 1. Summary of OPCML methylation in cell lines and
primary tumors.
Samples
Promoter
methylation (%)
Carcinoma cell lines
Nasopharyngeal 5/6 (83%)
Esophageal 15/17 (88%)
Lung 5/5 (100%)
Gastric 16/17 (94%)
Colorectal 11/11 (100%)
Hepatocellular 6/13 (46%)
Breast 9/10 (90%)
Cervical 8/10 (80%)
Prostate 2/3 (67%)
Lymphoma cell lines
Hodgkin’s lymphoma (HL) 6/6 (100%)
Burkitt lymphoma (BL) 6/6 (100%)
Diffuse large B-cell lymphoma (DLBCL) 5/5 (100%)
T-cell lymphoma (TL) 1/2 (50%)
NK/T-cell lymphoma (NL) 2/2 (100%)
Primary tumors
Nasopharyngeal Ca 42/43 (98%)
Esophageal Ca 21/32 (66%)
Hepatocellular Ca 4/7(57%)
Gastric Ca 7/11 (64%)
Colorectal Ca 17/18 (94%)
Breast Ca 10/11 (91%)
Cervical Ca 7/8 (88%)
Prostate Ca 0/5
Burkitt lymphoma 10/10 (100%)
Nasal lymphoma 8/9 (89%)
Immortalized normal epithelial cell lines
NP69, NE1, NE3, Het-1A, MLCSV40 0/5
Normal prostate epithelial cells (PrEC-6) 0/1
Normal tissues
Normal nasopharynx tissues 3(weak)/9 (33%)
Normal esophageal epithelial tissues 2(weak)/7 (29%)
Normal breast epithelial tissues 1/14 (7%)
Surgical-margin esophageal tissue from
esophageal Ca patients
5/32 (16%)
Surgical-margin breast tissue from breast Ca patients 1/4 (25%)
doi:10.1371/journal.pone.0002990.t001
Methylation of OPCML
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and breast) except for very weak methylation in three nasopha-
ryngeal, two esophageal and one breast epithelial tissues (Fig. 6A).
These results further demonstrated that methylation of OPCML-v1
promoter is frequent in multiple tumors. In contrast, no
methylation was detected in all five prostate cancer samples
(Fig. 6B).
Figure 3. High-resolution methylation analysis of the OPCML-v1 promoter by BGS. A region spanning the promoter with 90 CpG sites was
analyzed. Each CpG site is shown at the top row as an individual number. Dense methylation of the v1-CGI was found in ESCC (EC18, EC109) and NPC
(C666-1, CNE2, HK1) cell lines, but not in normal esophageal (NE1, NE3) and nasopharyngeal epithelial (NP69) cell lines. Five to 8 colonies of cloned
BGS-PCR products from each bisulfite-treated DNA sample were sequenced and each is shown as an individual row, representing a single allele of the
CGI analyzed. One circle indicates one CpG site. Dark filled or open circles represent methylated or unmethylated CpG sites, respectively. D indicates
possible variation of a CpG site to the CpA or CpT dinucleotides. The MSP region in this study and the BGS region studied in the previous report [20]
are indicated in frames. The rightmost column is the MSP result of each sample.
doi:10.1371/journal.pone.0002990.g003
Figure 4. Restorations of OPCML-v1 expression by demethylation. (A) Pharmacological demethylation by Aza (A) and TSA (T) induced the
expression of OPCML-v1 but not v2. OPCML expression before and after drug treatment was determined by RT-PCR. (B) Genetic demethylation of the
OPCML-v1 CGI also activated its expression. OPCML-v1 expression in HCT116 cells and HCT116 with double knockout of DNMT1 and DNMT 3B (DKO)
are shown. (C) Detailed BGS analysis confirmed the demethylation of the OPCML-v1 CGI in DKO cells.
doi:10.1371/journal.pone.0002990.g004
Methylation of OPCML
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Promoter methylation disrupted the stress response of
OPCML-v1
Examination of theOPCML promoter revealed multiple HSF and
p53 binding elements (MatInspector, http://genomatix.de), indi-
cating that it is a stress- and p53-responsive gene (Fig. 7A). We thus
inspected the response of OPCML to environmental stress stimuli.
We found that the expression of OPCML-v1 was dramatically
elevated in cell lines with an unmethylated promoter, after exposure
to various stresses, such as heat shock, UV irradiation and H2O2
treatment. On the contrary, this response was significantly
decreased or abolished in cell lines with a methylated promoter
(Fig. 7B). Interestingly, OPCML-v2 was not activated in any stress-
treated cell line, indicating that it is not stress-responsive, probably
due to its tissue-specific expression feature.
p53 could induce OPCML expression in the H1299 cell line with
a partially methylated promoter, in a dosage-dependent manner
(Fig. 7C). Taken together, these results demonstrated that OPCML
is a stress-responsive and p53-regulated gene but its stress response
is impaired by promoter methylation.
Ectopic expression of OPCML-v1 inhibited tumor cell
clonogenicity
The frequent silencing of OPCML-v1 in multiple tumor cell lines
and primary tumors but not normal epithelial tissues indicates that
OPCML-v1 is likely a tumor suppressor. We thus sought to
establish whether ectopic expression of OPCML-v1 could inhibit
tumor cell clonogenicity. A mammalian expression vector
encoding full-length OPCML-v1 was transfected into colorectal
Figure 5. Analysis of homozygous deletion of OPCML in multiple carcinoma cell lines and normal controls. The abundance of OPCML
relative to GAPDH was determined by multiplex differential genomic DNA PCR. The expression of OPCML in each sample is also shown. +, normal
expression; 2, downregulated/silenced.
doi:10.1371/journal.pone.0002990.g005
Figure 6. OPCML-v1 was also methylated in different primary tumors. (A) Frequent methylation of the OPCML-v1 CGI in multiple primary
tumors as analyzed by MSP. M, methylated; U, unmethylated. Representative results are shown. T, tumors; N, paired non-tumor tissues. Good quality
of bisulfited DNA samples of normal NPx (NPx1-4) has been confirmed by Q-MSP for beta-actin [44]. (B) In contrast, no methylation was detected in
prostate tumors. EsCa, esophageal carcinoma; HCC, hepatocellular carcinoma; GsCa, gastric carcinoma; BrCa, breast carcinoma; CxCa, cervical
carcinoma.
doi:10.1371/journal.pone.0002990.g006
Methylation of OPCML
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(HCT116), esophageal (KYSE510) and prostate (PC3) carcinoma
cell lines which had completely methylated and silenced
endogeous OPCML-v1 promoter (Fig. 2C). The colony formation
efficiencies of transfected cell line were evaluated by monolayer
and soft agar culture. Ectopic expression of OPCML-v1
significantly inhibited the anchorage-dependent growth of three
cell lines (down to 30%–60% of vector controls) (Fig. 8A and 8C).
Meanwhile, a significant reduction of colony formation efficiencies
was observed in anchorage-independent growth of HCT116 cells
(down to 30% of vector control) (Fig. 8B and 8C). Thus, OPCML-
v1 indeed has growth inhibitory activities in tumor cells and can
function as a tumor suppressor.
Discussion
We used a novel approach of combining DGED screening for
down-regulated genes with reported LOH data of NPC to search
for silenced candidate TSGs genome-wide in NPC and identified
OPCML. OPCML is frequently silenced by promoter methylation
rather than genetic deletion in NPC, as well as multiple other
carcinomas and lymphomas. We further showed that OPCML is a
stress-responsive and p53-regulated gene, with the response
abrogated when the promoter becomes methylated. In addition,
ectopic expression of OPCML in carcinoma cells lacking its
expression led to dramatic anchorage-dependent and –indepen-
dent growth inhibition. Thus, our results demonstrate that OPCML
is a broad functional tumor suppressor that is epigenetically
silenced in multiple tumors.
OPCML belongs to the IgLON family of immunoglobulin (Ig)
domain containing glycosylphosphatidylinositol (GPI)-anchored
cell adhesion molecules, which includes OPCML, LSAMP,
NEGR1 and HNT. The IgLON proteins are highly conserved
between species and are typically composed of three Ig domains
tethered to the surface of cell membrane by anchoring of their
hydrophobic tails to GPI. Limited knowledge about the functions
of IgLONs mainly derives from studies in rat and chick brain, the
tissues where they are primarily expressed [17,28,29]. In those
studies, IgLONs have been suggested to play an important role in
cell adhesion and cell-cell recognition, through both homo- and
hetero-philic interactions within the family [19]. Recently, it has
been proposed that IgLONs function mainly as heterodimers
called Diglons [30]. As a cell adhesion molecule, OPCML
comprises several protein-protein interaction domains, such as
three ‘C2’ like Ig domains [31] which are more appropriately
classified as ‘I’ set Ig domains [20], commonly found in cell-
surface-adhesion and receptor molecules [32]. Through these
domains, OPCML may bind directly to growth promoting or
inhibitory molecules and modulate their functions in tumor cells.
Among the IgLON family, OPCML was the first member reported
to possess tumor suppressor functions in epithelial ovarian cancer,
being frequently silenced genetically and epigenetically at the early
step of ovarian carcinogenesis [20]. This was followed by another
report that another IgLON, LSAMP, is also a TSG for renal clear
cell carcinoma [33]. Our present study further verifies that
OPCML can function as a broad TSG and is frequently inactivated
epigenetically in multiple carcinomas and lymphomas, including
NPC, esophageal, lung, gastric, hepatocellular, colorectal, breast,
cervical and prostate carcinomas. OPCML probably functions as a
tumor suppressor through interacting with other IgLONs to form
heterodimeric complex [30] involved in signal transduction. Loss
of OPCML reduces the intercellular adhesion and heterodimeric
complex formation and thus impairs the corresponding signaling
pathways, thereby promoting the progress of carcinogenesis.
OPCML shares the highest homology to HNT among the four
IgLON family members. Notably, the coding region in exon 1 of
OPCML-v1 andHNT is identical, and so is the exon 2 except for only
several bases. The first Ig domains of these two proteins share 92%
identity, while the second and third Ig domains share 70% and 66%
Figure 7. The OPCML-v1 promoter is stress- and p53-responsive. (A) Locations of transcription factors (HSF, p53, Sp1, E2F, STAT) binding sites
in the promoter are indicated. (B) Up-regulation of OPCML-v1 in response to stress treatments is disrupted in tumor cell lines with a methylated
promoter. Normal (NE3, HEK293, NE1) and tumor cell lines (Rael, CNE1, C666-1, HK1) were exposed to 42uC heat shock (HS), UV irradiation, or H2O2
treatments. OPCML-v1 promoter methylation status in each cell line is shown at the bottom. M, methylated; U, unmethylated. (C) H1299 cells were
transfected with different amounts of pcDNA3.1+/TP53 (gift from Dr. Bert Vogelstein) [27]. Expression of OPCML-v1 and v2 was analyzed by semi-
quantitative RT-PCR. p53 induced a dosage-dependent upregulation of OPCML-v1.
doi:10.1371/journal.pone.0002990.g007
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identity, respectively. This raises the possibility thatOPCML andHNT
may originate from the same ancestor by gene conversion during
evolution. Thus, primers must be cautiously designed for these two
genes to avoid cross-amplification with PCR-based techniques.
Our results also reveal that OPCML transcripts v1 and v2 have
different tissue expression patterns. Whereas OPCML-v1 was
widely expressed in normal adult tissues, OPCML-v2 showed a
more tissue-specific expression profile, being highly expressed in
few tissues including brain. Previously, a genome-wide searching
for the neuron specific silencer REST/NRSF binding sites (RE1/
NRSE) revealed that there were three NRSE located at intron 1 of
OPCML-v2 (http://bioinformatics.leeds.ac.uk/group/online/
RE1db/re1db_home.htm), suggesting that v2 may be a more
neuron specific transcript. We also identified other novel isoforms
of OPCML (v3, v4, v5, v6), derived from alternative splicing or
promoter usages. Using primers specific to the common exons of
OPCML transcripts, we found the expression of OPCML in several
tumor cell lines (Hep3B, H292, SW480, L1236), where the
OPCML-v1 and v2 were totally silenced (Fig. 1F), indicating
transcription of OPCML from alternative unknown promoters.
Our present study mainly focused on the expression and functional
analysis of transcript variant 1, whereas the mechanism of variant
2 silencing was not pursued further. Further studies are needed to
characterize these novel splicing variants, their promoter usages
and possible biologic functions.
Epigenetic gene silencing is associated with the onset and
progression of various cancers [2]. The frequent, predominant
epigenetic inactivation of OPCML in multiple malignancies points
to the importance of this gene in tumorigenesis. OPCML is a stress-
and p53-responsive gene, but this response was often epigeneti-
cally impaired by promoter methylation. We speculate that
epigenetic silencing of OPCML would impair the cellular protective
response to environmental stresses in normal cells, thus promoting
the development of cancers. As promoter methylation of OPCML
was pharmacologically and genetically reversible, pharmacologic
demethylation therapy will restore its response to stress and p53.
The role of OPCML in DNA damage repair, apoptosis and cell
cycle arrest with respect to stress response remains to be further
investigated. We also noticed that in some cell lines (like HCC),
OPMCL-v1 was silenced without promoter methylation detected
by MSP. It could be that for some cell lines, the methylation is not
evenly distributed through the CGI (like HepG2 in Fig. 3) and is
thus missed by MSP analysis, or additional alternative mechanism
such as histone modification is involved.
In summary, we found that the expression of OPCML-v1
(NM_002545), a major transcript of this TSG, is frequently
silenced or down-regulated in multiple tumors. This inactivation is
due to its promoter methylation, which further impairs its response
to environmental stresses. We further demonstrated that OPCML
acts as a broad tumor suppressor for multiple tumor types. The
high incidence of epigenetic inactivation of OPCML in NPC and
esophageal carcinoma, both prevalent in our locality, indicates
that OPCML methylation could be an epigenetic biomarker for the
molecular diagnosis of these tumors.
Figure 8. Ectopic expression of OPCML-v1 inhibits tumor cell growth. The effect of ectopic OPCML-v1 expression on carcinoma cell
clonogenicity was investigated by monolayer colony formation assay (A) and soft agar assay (B). Cells were transfected with pcDNA3.1+/OPCML-v1 or
control vector, and selected with G418. (C) Quantitative analyses of colony formation. The numbers of G418-resistant colonies in each vector-
transfected control were set to 100%, while OPCML-v1 expressed cells were presented as mean6SD. Three independent experiments were
performed in triplicate. The asterisk indicated statistical significant difference (p,0.01).
doi:10.1371/journal.pone.0002990.g008
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Materials and Methods
Cell lines, tumor and normal tissue samples
A series of tumor cell lines were studied, including nasopha-
ryngeal-NPC, esophageal, lung, gastric, colorectal, hepatocellular,
breast, cervical and prostate carcinomas, glioma, Hodgkin and
non-Hodgkin lymphomas, including Burkitt lymphoma (BL),
diffuse large B-cell lymphoma (DLBCL), T-cell lymphoma (TL)
and NK/T-cell lymphoma (NL) [12,13,26]. NP69, an SV40 T-
antigen-immortalized nasopharyngeal epithelial cell line with
many features of normal nasopharyngeal epithelial cells was used
as a ‘normal’ control for NPC [34]. Three immortalized normal
esophageal epithelial cell lines (NE1, NE3, Het-1A) [26,35] were
used as ‘normal’ controls for esophageal carcinoma. Colon
HCT116 cell lines with double knock-out of DNA methyltrans-
ferases (DNMTs): HCT116 DNMT12/2 DNMT3B2/2 (DKO)
cells (gifts from Dr Bert Vogelstein, Johns Hopkins) were used [25].
Total RNA and DNA were extracted from cell pellets using TRI
Reagent (Molecular Research Centre, Cincinnati, OH) as
reported previously [36]. Cell lines were treated with Aza (Sigma,
St. Louis, MO) and TSA as described previously [26].
Human normal adult and fetal tissue RNA samples were
purchased commercially (Stratagene, La Jolla, CA, USA or Millipore
Chemicon, Billerica, MA, USA) [26]. Human normal tissue DNA
samples were purchased from BioChain Institute (Hayward, CA).
DNA samples of normal esophageal epithelial tissues were described
previously [37,38]. DNA samples from various primary carcinomas
and their corresponding surgical marginal normal tissues (N), were
described previously [7,12,27,36,39–43].
Digital expression subtraction
We searched for downregulated genes genome-wide through
Differential Gene Expression Displayer (DGED) analysis (cDNA
DGED and SAGE DGED) (http://cgap.nci.nih.gov). This
analysis identified a number of downregulated genes in tumors.
The candidate gene list was further filtered with the reported loss
of heterozygosity (LOH) data of NPC. Genes located at published
LOH regions in NPC were extracted using UCSC genome
database (http://genome.ucsc.edu).
59-Rapid Amplification of cDNA Ends (59-RACE)
We determined the OPCML transcription start site using 59-
RACE version 2.0 (Invitrogen). Briefly, the first-strand cDNA was
synthesized from brain RNA using primer OPCML-DxR, 59-
TCCAGGTACTCATCCTCACT. Homopolymeric tails were
then added to the 39ends with terminal deoxynucleotidyl
transferase. PCR was done using Abridged Anchor Primer and
a second gene-specific primer OPCML-R2, 59-CTGCCAATAG-
CAAGACACAG. The RACE product was enriched by ream-
plifying with the Abridged Universal Amplification Primer and
OPCML-R, 59-TATGGACCACTTGTCATTCC, cloned and
sequenced.
Semi-quantitative RT-PCR analysis
Reverse transcription-PCR (RT-PCR) was performed for 36 or
37 cycles with hot-start, using AmpliTaq Gold DNA Polymerase
(Applied Biosystems, Foster City, CA) and GAPDH as a control
[36]. RT-PCR primers were designed to span introns to prevent
amplification of genomic DNA. Primer sequences are provided in
Table S1.
Bisulfite treatment and promoter methylation analysis
Bisulfite modification of DNA, methylation-specific PCR (MSP)
and bisulfite genomic sequencing (BGS) were carried out as
previously described [26,36]. Both MSP and BGS were performed
for 40 cycles using AmpliTaq Gold with hot-start. MSP primers
were tested first for not amplifying any unbisulfited DNA. For
BGS, the PCR products were cloned into pCR4-TOPO
(Invitrogen, Carlsbad, CA), with 5–8 colonies randomly chosen
and sequenced. Primer sequences are shown in Table S1.
Stress treatments
Heat shock was done as previously described [7], except for an
incubation at 42uC for 1 hour with recovery at 37uC for 2 hours. For
UV treatment, medium was removed and the flask was turned upside
down to face the light source in a UV cross-linker (Amersham
Biosciences, Piscataway, NJ). Cells were irradiated for a dose of 70 J/
m2. After irradiation, fresh medium was added, and the cells were
recovered at 37uC for 1 hour and then harvested. For H2O2
treatment, cells were exposed to 0.5 mM of H2O2 for 1 hour and
then harvested.
Deletion analysis of OPCML by multiplex PCR
Homozygous deletion of OPCML was examined using
multiplex genomic DNA PCR as previously described [7]. Primer
sequences are shown in Table S1. The final concentration of
OPCML and GAPDH primers is 0.4 mM and 0.2 mM, respectively.
PCR products were analyzed on 1.8% agarose gels.
Colony formation assays
The full-length OPCML-v1 ORF was subcloned from the
pcDNA3.1 Zeo/OPCML plasmid [20] into pcDNA3.1(+) to
generate pcDNA3.1+/OPCML-v1. HCT-116, KYSE510 and PC3
cells were seeded at 16105/well in a 12-well plate and allowed to
grow for 24h. Cells were then transiently transfected with 0.5 mg of
pcDNA3.1+/OPCML-v1 or pcDNA 3.1 vector alone, using
Fugene6.0 (Roche, Switzerland). For colony formation assay using
monolayer culture, cells were collected and plated in a 6-well plate
48h post-transfection, and selected for 1 to 2 weeks with G418
(0.4mg/ml). Surviving colonies ($50 cells/colony) were counted
after staining with Gentian Voilet (ICM Pharma, Singapore). For
colony formation assay using soft agar culture, at 48h post-
transfection, cells were suspended in RPMI 1640 containing 0.35%
agar, 10% fetal bovine serum and 0.4 mg/ml G418 and layered on
RPMI containing 0.5% agar, 10% fetal bovine serum and G418 in
a 6-well plate. Colonies were photographed at day 20 post-
transfection. All the experiments were performed in triplicate wells
for three times. Data were presented as relative colony formation
ability6SD. Statistical analysis was carried out by Student’s t-test,
p,0.01 was considered as statistically significant difference.
Supporting Information
Table S1 PCR primers used in this study.
Found at: doi:10.1371/journal.pone.0002990.s001 (0.07 MB
DOC)
Figure S1 Expression and methylation of OPCML in Hodgkin
and non-Hodgkin lymphoma cell lines.
Found at: doi:10.1371/journal.pone.0002990.s002 (0.17 MB TIF)
Figure S2 Methylation status of the OPCML-v1 in multiple
normal adult and fetal tissues as analyzed by MSP.
Found at: doi:10.1371/journal.pone.0002990.s003 (0.11 MB TIF)
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